Abstract
Acute uncomplicated cystitis is one of the most prevalent community-acquired infections in urological practice. One of the crucial moments in the therapy of urinary tract infections is the administration of antibacterial drugs. The following groups of antimicrobials should be used in the treatment of acute uncomplicated cystitis: fluoroquinolones, trimethoprim/sulfamethoxazole, nitrofurans, fosfomycin trometamol and beta-lactams. This article shows the current aspects of antibiotic choice depending on the etiology and antibiotic resistance of uropathogens causing acute uncomplicated cystitis as well as efficacy and safety of the above mentioned antimicrobials
-
1.
Лопаткин Н.А., Деревянко И.И. Неосложненные и осложненные инфекции мочеполовых путей. Принципы антибактериальной терапии. РМЖ 1997; (24):1579-88.
-
2.
Страчунский Л.С., Рафальский В.В., Сехин С.В., Абрарова Э.Р. Практические подходы к выбору антибиотиков при неосложненных инфекциях мочевыводящих путей. Урология 2002; (2):8-14.
-
3.
Моисеев С.В. Практические рекомендации по антибактериальной терапии, профилактике инфекций мочевыводящих путей с позиций доказательной медицины. Инфекции и антимикробная терапия 2003; (5):89-92.
-
4.
Naber K.G. Optimal management of uncomplicated and complicated urinary tract infections. Adv Clin Exp Med 1998; (7):41-6.
-
5.
Hooton T.M., Scholes D., Hughes J., et al. A prospective study of risk factors for symptomatic urinary tract infections in young women. N Engl J Med 1996; (335):468- 74.
-
6.
Лоран О.Б. Инфекции мочевыводящих путей у амбулаторных больных: Материалы симпозиума. М., 1999; 5-9.
-
7.
Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002; 113(suppl.1A):5S-13S.
-
8.
Hooton T.M., Stamm W.E. Diagnosis and treatment of uncomplicated urinary tract infection.Infect Dis Clin North Am. 1997;11:551-81.
-
9.
Foxman B. Recurring urinary tract infection: incidence and risk factors. Am J Public Health 1990; 80:331-3.
-
10.
Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS project. J Antimicrob Chemother 2003; 51:69-76.
-
11.
Многоцентровое исследование резистентности возбудителей амбулаторных инфекций мочевыводящих путей (UTIAP-3). Научный отчет НИИ антимикробной химиотерапии Смоленск, 2006.
-
12.
Schito G.C., Naber K.G., Botto H., et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009; 34:407-13.
-
13.
Warren J.W., Abrutyn E., Hebel J.R., et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999; 29:745-58.
-
14.
Raz R., Chazan B., Kennes Y., Colodner R., Rottensterich E., Dan M., Lavi I., Stamm W., Israeli Urinary Tract Infection Group. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 2002; 34:1165-9.
-
15.
McCarty J.M., Richard G., Huck W., Tucker R.M., Tosiello R.L., Shan M., Heyd A., Echols R.M. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group. Am J Med 1999; 106:292-9.
-
16.
Hooton T.M. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. Int J Antimicr Agents 2003; 22(suppl.2):65-72.
-
17.
Guay D.R. An update on the role of nitrofurans in the management of urinary tract infections. Drugs 2001; 61:353-64.
-
18.
Cunha B.A. Antibiotic side effects. Med Clin North Am 2001; 85:149-85.
-
19.
Brumfitt W., Hamilton-Miller J.M. Efficacy and safety profile of long-term nitrofurantoin in urinary infections: 18 years’ experience. J Antimicrob Chemother 1998; 42:363-71.
-
20.
Karpman E., Kurzrock E.A. Adverse reactions of nitrofurantoin, trimethoprim and sulfamethoxazole in children. J Urol 2004; 172:448-53.
-
21.
Goettsch W.G., Janknegt R., Herings R.M. Increased treatment failure after 3-days’ courses of nitrofurantoin and trimethoprim for urinary tract infections in women: a population-based retrospective cohort study using the PHARMO database. Br J Clin Pharmacol 2004; 58:184- 9.
-
22.
Kahan F.M., Kahan J.S., Cassidy P.J., Kropp H. The mechanism of action fosfomycin (phosphonomycin). Ann N.Y. Acad Sci 1974; 235:364-86.
-
23.
Zhanel G.G., Nicolle L.E. Effect of subinhibitory antimicrobial concentrations (sub-MICs) on in vitro bacterial adherence to uroepithelial. J Antimicrob Chemother 1992; 29:617-27.
-
24.
Carlone N.A., Borsotto M., Cuffini A.M., Savoia D. Effect of fosfomycin trometamol on bacterial adhesion in comparison with other chemotherapic agents. Eur Urol 1987; 13(suppl.1):86-91.
-
25.
Аляев Ю.Г., Винаров А.З., Воскобойников В.Б. Острый цистит: этиология, клиника, лечение. Лечащий врач 2002; 4.
-
26.
Daza R., Gutierrez J., Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents 2001; 18:211-5.
-
27.
Синякова Л.А., Косова И.В. Применение фосфомицина трометамола в лечении инфекций нижних отделов мочевыводящих путей. Клин микробиол антимикроб химиотер 2005; 7(2):183-8.
-
28.
Лоран О.Б., Страчунский Л.С., Рафальский В.В., Синякова Л.А., Косова И.В., Шевелев А.Н. Микробиологическая характеристика и клиническая эффективность фосфомицина. Урология 2004; 3:18-21.
-
29.
Lecomte F., Allaert F.A. Single-dose treatment of cystitis with fosfomycin trometamol (Monuril): analysis of 15 comparative trials on 2048 patients. Giorn It Ost Gin 1997; 19:399-404.
-
30.
Minassian M.A., Lewis D.A., Chattopadhyay D., Bovill B., Duckworth G.J., Williams J.D. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents 1998; 10:39-47.
-
31.
Ko K.S., Suh J.Y., Peck K.R., et al. In vitro activity of fosfomycin against ciprofloxacin-resistant or extendedspectrum beta-lactamase-producing Escherichia coli isolated from urine and blood. Diagn Microbiol Infect Dis 2007; 58: 111-15.
-
32.
Ungheri D.E., Albini E., Belluco G. In-Vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol. J Chemother 2002; 14:237- 40.
-
33.
Pullukcu H., Tasbakan M., Sipahi O.R., Yamazhan T., Aydemir S., Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007; 29:62-5.
-
34.
Falagas M.E., Kastoris A.C., Karageorgopolous D.E., Rafailidis P.I. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gramnegative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009 (в печати).
-
35.
Рафальский В.В., Быстрюков В.Ю. Рациональная терапия инфекций мочевыводящих путей: возможности использования данных систематических обзоров и метаанализов. Consilium Medicum 2006; 4:17- 21.
-
36.
De Jong Z., Pontonnier F., Plante P. Single-dose fosfomycin trometamol (Monuril) versus multiple-dose norfloxacin: results of a multicenter study in females with uncomplicated lower urinary tract infections. Uro Int 1991; 46:344-8.
-
37.
Boerema J.B., Willems F.T. Fosfomycin trometamol in a single dose versus norfloxacin for seven days in the treatment of uncomplicated urinary infections in general practice. Infection 1990; 18(suppl2):80-8.
-
38.
Набер К., Бергман Б., Бишоп М. и соавт. Рекомендации Европейской ассоциации урологов по лечению инфекций мочевыводящих путей и инфекций репродуктивной системы у мужчин. МАКМАХ, 2007. - 223 с.